3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
300
Carcinoma, Non-Small-Cell Lung
225
Neoplasms
195
Prostatic Neoplasms
164
Multiple Myeloma
139
Neoplasm Metastasis
117
Melanoma
113
Colorectal Neoplasms
108
Leukemia, Myeloid, Acute
107
Lung Neoplasms
98
Lymphoma
97
Ovarian Neoplasms
87
Squamous Cell Carcinoma of Head and Neck
77
Lymphoma, Non-Hodgkin
73
Leukemia, Lymphocytic, Chronic, B-Cell
72
Myelodysplastic Syndromes
65
Triple Negative Breast Neoplasms
64
Pancreatic Neoplasms
64
Hematologic Neoplasms
60
Parkinson Disease 4, Autosomal Dominant Lewy Body
59
Head and Neck Neoplasms
59
Glioblastoma
58
Precursor Cell Lymphoblastic Leukemia-Lymphoma
57
Recurrence
56
Leukemia
56
Sarcoma
50
Brain Neoplasms
50
Lymphoma, Large B-Cell, Diffuse
48
Carcinoma, Hepatocellular
47
Lymphoma, Follicular
46
Interventions
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hemangioma, Cavernous, Central Nervous System
×
1 year
×
Clear all
NCT02603328
2025-08-22
AT CASH EPOC
University of Chicago
Phase 1/2
Completed
80 enrolled
19 charts